Moreover, an OS advantage was also recorded for the whole ESCC population (HR 0.72), PD-L1 CPS of 10 or more with HR 0.62, and in all randomized patients (HR 0.73). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.